Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DSM In India Gets Neighborly With Nutritional Ingredient Customers

This article was originally published in The Tan Sheet

Executive Summary

The Dutch conglomerate DSM will open a dietary supplements manufacturing site in India, where the company forecasts strong growth. While DSM currently distributes ingredients from plants in other countries to India, the facility will provide its customers quicker lead times for customized nutrient blends.

You may also be interested in...



Fortitech Deal Fills Gap In DSM’s Nutritional Portfolio

DSM’s announcement of its $634 million cash acquisition of Fortitech follows the firm’s report that its nutritional business was the key sales driver in its latest earnings period. Fortitech adds macro-blend manufacturing for human nutritional products to DSM’s supply chain.

DSM Forms 50-50 Joint Venture With Sinochem To Crack Into China's Restricted Anti-Infectives Market

SHANGHAI - Netherlands-based Royal DSM announced Dec. 17 that it reached an agreement with Sinochem Group, one of China's biggest central state-owned enterprises, to form a global 50-50 joint venture for anti-infectives. The two companies expect to close the transaction in Q2 2011

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Topics

Related Companies

UsernamePublicRestriction

Register

PS106838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel